Novel methods of treating hearing loss
US-2024390323-A1 · Nov 28, 2024 · US
Pharmaceutical composition for ANO1 antagonist with anticancer activity
US11274074B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11274074-B2 |
| Application number | US-201916574701-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 18, 2019 |
| Priority date | Sep 19, 2018 |
| Publication date | Mar 15, 2022 |
| Grant date | Mar 15, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to a novel anticancer pharmaceutical composition. The present disclosure achieves an anticancer effect using a compound effective in inhibiting the expression of ANO1 (TMEM16A). In addition, the present disclosure provides an ANO1 (TMEM16A) antagonist using the compound inhibiting the expression of ANO1 (TMEM16A).
First claim
Opening claim text (preview).
What is claimed is: 1. An anticancer pharmaceutical composition comprising a compound represented by [Chemical Formula 5]: as an active ingredient. 2. The anticancer pharmaceutical composition according to claim 1 , wherein the compound represented by Chemical Formula 5 has an IC 50 [μM] for ANO1 (TMEM16A) of 0.01-65. 3. The anticancer pharmaceutical composition according to claim 1 , wherein the compound represented by Chemical Formula 5 has an IC 50 [μM] for ANO1 (TMEM16A) of 0.01-0.08.
Assignees
Inventors
Classifications
Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006) · CPC title
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2 · CPC title
Oxadiazoles · CPC title
Antineoplastic agents · CPC title
condensed with carbocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11274074B2 cover?
- The present disclosure relates to a novel anticancer pharmaceutical composition. The present disclosure achieves an anticancer effect using a compound effective in inhibiting the expression of ANO1 (TMEM16A). In addition, the present disclosure provides an ANO1 (TMEM16A) antagonist using the compound inhibiting the expression of ANO1 (TMEM16A).
- Who is the assignee on this patent?
- Univ Yonsei Iacf
- What technology area does this patent fall under?
- Primary CPC classification A61K31/165. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).